Created by: Hellenbrecht (ELIC) , generated 2006/03/14, last changed: 2008/06/04

 

Name	Initials	E-mail	Clinic	Country
Lead Participants
T. Buechner	BUE		Universitätsklinikum Münster	Germany
G. Ossenkoppele	OSS		VU Academic Medical Center	Netherlands
M. Sanz	SAN		Fundación Hospital Universitario "La Fe"	Spain
Participants
S. Amadori	AMA		Universitá degli Studi di Roma Tor Vergata	Italy
W. Berdel	BERD			Germany
M. Björkholm	BJO		Karolinska Institutet	Sweden
M. Boogaerts	BOO		Katholieke Universiteit Leuven	Belgium
A. Burnett	BUR		University of Wales, College of Medicine	UK
C. Chomienne *	CHO			France
T. de Witte	DEW		Stichting Katholieke Universiteit, University Medical Center Nijmegen	Netherlands
H. Döhner	DOE		Universität Ulm	Germany
H. Dombret	DOM			France
C. Driessen	DRI			Germany
G. Ehninger	EHN		Technische Universität Dresden	Germany
P. Fenaux	FEN		Hopital Avicenne (CHU Paris 13)	France
A. Ganser	GAN		Medizinische Hochschule Hannover	Germany
U. Germing	GERM			Germany
D. Grimwade	GRI			UK
J. Hasford	HAS			Germany
A. Heinecke	HEI			Germany
P. Hokland	HOK		Aarhus University Hospital	Denmark
J. Holowiecki	HOLO		Medical University of Silesia	Poland
K. Indrak	IND			Czech Republic
L. Kanz	KAN			Germany
J. Kienast	KIE			Germany
W. Köpcke	KÖP			Germany
U. Krug	KRU			Germany
K. Lechner	LEC		Medizinische Universität Wien	Austria
S. Lehmann	LEH			Sweden
E. Lengfelder *	LEN		Ruprecht-Karls-Universität Heidelberg	Germany
B. Löwenberg	LOE		Erasmus University Medical Center Rotterdam	Netherlands
M. Lübbert	LUEB			Germany
F. Mandelli	MAN		Dipartimento di Biotecnologie Cellulari ed Ematologia, Università degli Studi di Roma "La Sapienza"	Italy
J.P. Marie	MAR		Université Pierre et Marie Curie 6	France
R. Martino	MARR			Spain
D. Niederwieser	NIED		Universität Leipzig	Germany
M. Pfirrmann	PFI			Germany
P. Ribaud *	RIB			France
J.M. Rowe	ROW		Fund for Medical Research Development of Infrastructure and Health Services, Rambam Medical Center	Israel
M.C. Sauerland	SAUE			Germany
V. Savchenko *	SAV		National Research Center for Hematology	Russia
H. Serve	SER		Universitätsklinikum Frankfurt	Germany
J. Sierra	SIE		Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau	Spain
P. Valent	VAL		Medizinische Universität Wien	Austria
R. Willemze	WILL		Leiden University Medical Center	Netherlands
A. Zelent	ZEL			UK
* = Female Researcher

Lead Participants:

Prof.Dr. T. Buechner (Münster, Germany): Chairman of the AML Cooperative Group since 1978 (participating centers: 50, annual patient recruitment: 350). Initiation and organization of the German AML Intergroup combining 5 trial groups. Main fields of research: Treatment optimization for AML, prognostic factors, treatment effects specific to biologic subgroups, growth factors, novel therapeutics, networking among trials.

Prof.Dr. G. Ossenkoppele (Amsterdam, Netherlands): Dept. of Hematology, University of Amsterdam. Chairman HOVON AML Study Group. Main field of research: Treatment of acute and chronic leukemias, myelodysplastic syndromes, autologous stem cell transplantation, therapeutic trials in AML, chairman HOVON AML Study Group.

M. Sanz (Valencia, Spain): Chairman Spanish PETHEMA Study Group. Chairman Spanish Hematopoietic Transplantation Group (GETH). Lead participant of project „Targeting chromatin in cancer histone deacetylases and differentiation therapy of acute myeloid leukemias“ supported by 5th Framework of EC. Main field of research: Clinical research in hematology, leukemias and myelodysplastic syndromes.

Participants:

Prof.Dr. S. Amadori (Rome, Italy): Longstanding experience in the diagnosis and treatment of hematologic malignancies.

W. Berdel (, Germany):

Prof.Dr. M. Björkholm (Stockholm, Sweden): 1995 – Professor of Medicine, Karolinska Institutet and Hospital Stockholm. Chairman Leukemia Group of Middle Sweden. Main field of research: Molecular genetics, molecular cytogenetics in AML and MDS, treatment strategies, MDR modulation.

Prof.Dr. M. Boogaerts (Leuven, Belgium): Head Dept. of Hematology, University of Leuven, Belgium. Chairman HOVON AML Study Group. Main field of research: Hematopoietic progenitor cells, pathophysiology of MDS, studies on bone marrow cultures, monitoring MRD, stem cell transplantation, granulocyte physiology, cord blood studies and banking.

Prof.Dr. A. Burnett (Cardiff, UK): Chairman Medical Research Council Leukemia Clinical Trials. Main fields of research: Treatment optimization in AML, role of autologous transplantation and allogeneic transplantation, differential treatment effects in prognostic subgroups, risk-adapted treatment strategies, treatment of acute promyelocytic leukemia.

C. Chomienne (, France):

Prof.Dr. T. de Witte (Nijmegen, Netherlands):

Prof.Dr. H. Döhner (Ulm, Germany): Head Department of Medicine, Oncology, Rheumatology, Infectious Diseases, University of Ulm. Chairman of the AML study group Heidelberg/Ulm. Co-Chairman in the German AML Intergroup.

Prof.Dr. H. Dombret (, France):

C. Driessen (, Germany):

Prof.Dr. G. Ehninger (Dresden, Germany): Head Department of Medicine, University of Dresden. Chairman of the SHG AML 96 study group, Co-Chairman in the German AML Intergroup.

Prof.Dr. P. Fenaux (Paris, France): Professor of Hematology, University of Paris. Head Hematology Service Hôpital Beaujon and Hôpital Avicenne. Chairman study group on APL, tAML and molecular genetics of AML. Main field of research: epidemiology of chemotherapy induced leukemias and myelodyplastic syndromes, acute promyelocytic leukemia, European trial on treatment with retinoids, the role of autologous transplantation, MDR modification by quinine, treatment of myelodysplastic syndromes and biology and molecular biology of APL.

Prof.Dr. A. Ganser (Hannover, Germany): Head Dept. Medicine, Hematology and Oncology, Hannover Medical School. Co-Chairman AML-SHG Hannover Study Group. Co- Chairman in the German AML Intergroup.

U. Germing (, Germany):

D. Grimwade (, UK):

Prof.Dr. J. Hasford (, Germany):

A. Heinecke (, Germany):

Prof.Dr. P. Hokland (Aarhus, Denmark): Head of research group for molecular genetics in leukemias. Main field of research: MRD, advanced molecular techniques such as multiplex PCR, RQ-PCR, control genes for fusion transcripts, molecular effects of Imatinib, gene profiling in translocation negative acute leukemias.

Prof.Dr. J. Holowiecki (Katowice, Poland): Head University Dept. of Hematology and Bone Marrow Transplantation, Silesian Medical Academy, Katowice. Head Polish Adult Leukemia Group (PALG). Main field of research: the role of 2-CdA together with AraC/DNR in AML.

K. Indrak (, Czech Republic):

L. Kanz (, Germany):

J. Kienast (, Germany):

W. Köpcke (, Germany):

U. Krug (, Germany):

Prof.Dr. K. Lechner (Vienna, Austria): Professor of Medicine, University of Vienna. 1992 – Head Div. of Hematology and Blood Coagulation, General Hospital Vienna. 2000 – Head of I. Dept. of Medicine, General Hospital Vienna. 1991-1997 President Austrian Society of Hematology and Oncology. 1988 Congress President German and Austrian Society of Hematology and Oncology. Main field of research: Acute leukemia treatment, molecular biology, prognostic factors, role of cytokines, bone marrow transplantation. Coagulation disorders, thrombophilia.

S. Lehmann (, Sweden):

PD Dr. E. Lengfelder (Heidelberg, Germany): Physician at the III. Medizinische Klinik Mannheim, University of Heidelberg. Main areas of research are the development of clinical trials in acute promyelocytic leukemia and chronic myeloproliferative disorders. Chairperson of the national polycythemia vera study group.

Prof.Dr. B. Löwenberg (Rotterdam, Netherlands): Professor of Hematology. Chairman Department of Hematology, Erasmus University Medical Center, Rotterdam. Major research interests in stem cell transplantation, diagnosis and treatment of leukemia and pathobiology of leukemia. Member of the Royal Academy of Sciences and Arts, The Netherlands. Editorial Board of The New England Journal of Medicine, Boston. Chairman of the Council of Medical Research of the Royal Academy of Sciences and Arts, The Netherlands. Committee of the Netherlands Health Council on Hematopoietic Stem Cells. Board of the Netherlands Cancer Society (“Queen Wilhelmina Fund”).

M. Lübbert (, Germany):

Prof.Dr. F. Mandelli (Rome, Italy): Director of the Institut of Hematology of the University “La Sapienza” of Roma, the largest in Italy. Over the years the main priorities have been the design of original therapeutic protocols for numerous clinical trials in acute leukemias including intensive chemotherapy and transplantation. He has over 700 scientific publications in the most important national and international journals.

Prof.Dr. J.P. Marie (Paris, France): Longstanding experience in the diagnosis and treatment of hematologic malignancies.

R. Martino (, Spain):

Prof.Dr. D. Niederwieser (Leipzig, Germany):

M. Pfirrmann (, Germany):

P. Ribaud (, France):

Prof.Dr. J.M. Rowe (Haifa, Israel): Director Dept. of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa. 1991-97 Professor of Medicine, University of Rochester. 1993-98 Leukemia committee chairman of ECOC. 1980 – Chairman of multiple clinical studies of ECOC including those addressing the role of growth factors, supportive and priming effects, chemotherapy strategies in induction and postremission treatment, autologous and allogeneic transplantation, treatment of older patients. Main field of present research: alternative donor transplants, haplo-identical transplantation (cooperation in EBMT), farnesyl transferase inhibitors, troxacytabine in AML.

M.C. Sauerland (, Germany):

Prof.Dr. V. Savchenko (Moscow, Russia): Head Russian Leukemia Research Group. Clinical and biological investigation of AML including APL. Relevant publications: Sadovnikova et al. Leukemia 16, 2019-26, 2002.

Prof.Dr. H. Serve (Frankfurt, Germany):

Dr. J. Sierra (Barcelona, Spain): Head Clinical Hematology Divison, Hospital de la Santa Creu i Sant Pau, Barcelona. Chairman Spanish CETLAM Group. Main field of research: hematopoietic transplantation.

Prof.Dr. P. Valent (Vienna, Austria): 1997 – Professor of Medicine at Dept. of Medicine I, Div. of Hematology and Hemostaseology, Vienna, Austria. 1992 – Senior research scientist, University of Vienna. Chairman of a Leukemia Study Group at University of Vienna. Main field of research: MDS and AML, leukemic stem cells, mast cells and mastocytosis, c-kit mutations, cytokines and receptors microvasculature, vasoactive peptides.

Prof.Dr. R. Willemze (Leiden, Netherlands): Head Department of Hematology, University of Leiden. Member and active participant EORTC Leukemia Group. 1993-2000 Chairman EORTC Leukemia Group. Since 2000 coordinator EORTC acute leukemia studies. 1985-1998 Protocol review committee of EORTC. Founding member Dutch HOVON. 1996-2000 Secretary Netherlands Society of Hematology. Since 2000 Chairman Netherlands Society of Hematology. Secretary Dutch Bone Marrow Bank and founder of Dutch Cord Blood Bank.

A. Zelent (, UK):